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A mild TCEP-based para-azidobenzyl cleavage
strategy to transform reversible cysteine thiol
labelling reagents into irreversible conjugates†
Antoine Maruani, Shamim Alom, Pierre Canavelli, Maximillian T. W. Lee,
Rachel E. Morgan, Vijay Chudasama* and Stephen Caddick
It has recently emerged that the succinimide linkage of a maleimide
thiol addition product is fragile, which is a major issue in fields
where thiol functionalisation needs to be robust. Herein we deliver
a strategy that generates selective cysteine thiol labelling reagents,
which are stable to hydrolysis and thiol exchange.
Advances in proteinmodification by chemical means have led to the
development of a range of protein bioconjugation methodologies.1
These methodologies have been successfully applied to a number of
fields such as the fluorescent tagging of proteins,2 and the develop-
ment of therapeutic protein conjugates3,4 to treat indications such as
HIV,5 cancer,6 and malaria.7 Chemically modified proteins are also
utilised as diagnostics.8
The use of synthetic methodology to modify proteins has to
overcomemanymajor obstacles, the most significant of which is the
need for high selectivity, i.e. modifying only one amino acid type by
discriminating against the other natural amino acids in a protein.9
As free cysteines are extremely rare in proteins10 and the thiol side
chain has the highest nucleophilicity of all proteinogenic groups at
physiological conditions,11 it is a very popular target for the selective
and site-specific modification of proteins.12 Moreover, with the
possibility of facile cysteine introduction by site-directed mutagen-
esis, cysteine modification is a leading approach. The most popular
strategy for labelling the thiol moiety of cysteine residues is by
alkylation with maleimides to form thioether-succinimides.12,13
However, it has recently come to light that such an appendage is
sub-optimal owing to issues of hydrolysis, and thiol exchange with
reactive thiols in the blood (e.g. albumin).14 This has major implica-
tions for biologics that employ a maleimide motif to functionalise a
protein thiol for in vivo applications. For example, in antibody-drug
conjugates (ADCs), where an antibody delivers a toxic payload to
cancerous tissue selectively, the use ofmaleimides to attach cytotoxic
drugs to an antibody is not ideal as thiol exchange onto human
serum albumin in the blood results in oﬀ-site toxicity.14
Although recent advances have been made in this area through
the use of hydrolysedmaleimides and succinimides,14,15 a strong
drive to develop novel reagents for reliable, chemoselective,
stable and irreversible thiol labelling remains, and particularly
for the construction of ADCs.16
Recently, we have described a novel, reversible approach to
cysteine bioconjugation through the use of bromomaleimides
and bromopyridazinediones.17 To date, our approach has provided
access to complex bioconjugates in high yields, without prior
activation of reagents with reliable, reversible conjugation. Owing
to the demand for hydrolytically stable and thiol irreversible
bioconjugates that react in a chemoselective manner, we naturally
sought to explore the use of reagents that wouldmeet these criteria.
During the course of developing bromopyridazinediones for rever-
sible cysteine bioconjugation, we became intrigued by the prospect
of pyridazinediones (PDs) as irreversible cysteine functionalisation
reagents. Previously we have shown that if one of the nitrogen
atoms on the PD core is unsubstituted the molecule does not react
with thiols at physiological pH or higher.17a We postulate that this
is a consequence of such a structure existing as its enol tautomer,
which is likely to be significantly deprotonated under physiological
Fig. 1 A novel strategy for developing thiol-stable pyridazinedione
bioconjugates.
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pH (or higher), based on the reported pKa of 1-methyl-3,6-(1H,2H)-
pyridazinedione being B5.7 in H2O and the calculated pKa of its
thioether analogue,‡ 1-methyl-4-(methylthio)-3,6-(1H,2H)-pyridazine-
dione, being B5.9.18 Thiol reactivity will therefore be greatly
reduced as the electrophilicity of the resulting PD-core moiety
will be tuned down considerably. As such, we set about developing
a strategy where we could generate a mono-alkylated-PD species
post-bioconjugation to a cysteine thiol to aﬀord a thiol stable
construct (see Fig. 1).
Our study began with the reaction of model protein GFP-S147C 1
with pyridazinediones 2 and 3 to confirm our previous observations
when using protein Grb2-L111C (see Fig. 2).17a These results were
consistent with our previous work and confirmed that a mono-
alkylated-PD is unreactive to thiol (or other nucleophilic functional
groups on amino acid side-chains).
These initial studies paved the way for us to appraise the use of a
novel strategy for developing thiol-stable pyridazinedione bioconjugates
(see Fig. 1). To do so, we needed to develop a selective method for
cleavage of R2 from the PD core. There are many strategies that could
be applied, however, at this juncturewe took the opportunity to develop
a novel, mild and simplemethod based on an azide trigger. Our desire
to use an azide-based cleavable handle originates from the bioortho-
gonality of the azide functional group. Taking inspiration from thewell-
documented work on p-aminobenzyloxycarbonyl (PABC) linkers,19 we
set about using a p-azidobenzyl cleavage strategy (see Fig. 3).
We initially evaluated our p-azidobenzyl cleavage strategy in
a small molecule study through the use of cysteine derivative 6,
formed by reaction of N-(tert-butoxycarbonyl)-L-cysteine methyl
ester andmono-bromo PD 5 (see ESI† for details on synthesis). The
use of an alkyne handle, which would conceptually be retained post
p-azidobenzyl cleavage, would allow for the resulting construct
to be readily functionalised by a Cu(I)-catalyzed Azide-Alkyne
Cycloaddition (CuAAC). To our delight, treatment of derivative
6 with TCEP led to clean conversion to derivative 7, thus
providing proof of concept for our novel cleavage strategy.
Moreover, incubation of derivatives 6 and 7 with 15 equivalents
of 1-hexanethiol in THF/PBS buﬀer (pH 7.4) only led to thiol
exchange in the case of derivative 6. This provided encourage-
ment for our hypothesis of a mono-alkylated-PD being thiol
unreactive under physiological pH or higher (Fig. 4).
Following these encouraging results on a small molecule study,
we appraised our strategies on amodel protein with a single cysteine
mutation, GFPS147C 1. Initially, GFPS147C 1 was incubated with
mono-bromo-PD 5 in sodium phosphate buﬀer (pH 8.0) for 1 h at
37 1C. As expected, this proceeded with complete conversion and
aﬀorded GFP-derivative 8. We next applied our TCEP cleavage
strategy, by incubation of this derivative with 10 equivalents of
TCEP in phosphate buﬀer at pH 8.0. Satisfyingly, clean conversion
to bioconjugate 9 was observed, which is consistent with our small
molecule study. It is also noteworthy that no hydrolysis occurred
under these conditions, which is consistent with our previous
observations on the PD core being hydrolytically stable.17a
Fig. 2 Incubation of GFPS147C 1 with pyridazinediones 2 and 3.
Fig. 3 Use of a p-azidobenzyl cleavage strategy to generate a thiol-stable
pyridazinedione bioconjugate.
Fig. 4 Use of TCEP in our p-azidobenzyl cleavage strategy to generate
pyridazinedione derivative 7 from derivative 6, and the thiol stability of
each construct.
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Having established, using mass spectrometry, that our cleavage
strategy is applicable on a protein, we next compared the thiol
stability of 8 and 9 by incubation with glutathione (0.5 mM) for 72 h
at pH 7.4 and 37 1C. Gratifyingly, GFP-derivative 9 was completely
stable under the reaction conditions, whereas derivative 8 showed
complete thiol exchange with glutathione. This therefore established
proof of concept for both our strategies on a model protein scaﬀold.
Moreover, this work also highlights the versatility of the PD platform
with a facile shift from reversible to irreversible constructs achieved
under mild conditions (Fig. 5).
Following our work on developing a novel p-azidobenzyl
cleavage strategy and obtaining a thiol stabile construct, we set
about functionalising protein scaﬀold 9 by the use of ‘click’
chemistry. If successful, this would result in a facile method for
functionalising the thiol-stable bioconjugate. A number of ‘click’
conditions were trialled using benzyl azide as our model azide.
The most promising conditions were the use of Cu(I)Br as copper
source and THPTA as ligand. These conditions gave complete
conversion of starting material alkyne 9 to triazole bioconjugate
10a. Moreover, these conditions also allowed for clean reaction
of the alkyne derivative with a dansyl azide and a sulfo-cyanine5
azide to aﬀord 10b and 10c, respectively (Fig. 6).
In conclusion, we have developed, via a novel p-azidobenzyl
cleavage strategy, a route to thiol stable cysteine-bioconjugates that
has a clear advantage over conventional maleimide chemistry.
The strategy has been demonstrated on both a small molecule
system and on a model protein, GFPS147C. Owing to the plethora
of fields where thiol functionalisation needs to be robust and
irreversible, e.g. in antibody-drug conjugates (ADCs), imaging and
theranostics, we believe this work will find use in a variety of
domains. We hope to deliver on the application of our platform
in a range of contexts, including ADCs, in the near future.
The authors gratefully acknowledge the EPSRC, Ramsay
Memorial Trust and UCL for support of our programme.
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